Adimmune Corporation
4142
Rank in Stocks
#16354
Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the... Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influenza vaccine, AdimFlu-S, alongside trivalent influenza vaccines and the Influenza A (H1N1) Virus Monovalent Vaccine. The company also provides tetanus toxoid products, vital for post-injury tetanus prevention, and Japanese encephalitis vaccines. Furthermore, Adimmune supplies purified Tuberculin and extends its expertise through contract manufacturing services. Established in 1965, the company initially operated under the name Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. It subsequently rebranded as Adimmune Corporation in 2001 and maintains its headquarters in Taichung, Taiwan.
Share Price
$0.50909046
Last synced: 2026-11-10
Market Cap
$214.59M
Change (1 day)
0.00%
Change (1 year)
-16.29%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Adimmune Corporation (4142)
Category
Healthcare
Operating Margin for Adimmune Corporation (4142)
Operating Margin as of November 2026 TTM: -18.85%
According to Adimmune Corporation's latest financial reports, its current operating margin (TTM) is -18.85%. At the end of 2025 the company had an operating margin of -25.65%.
Operating Margin history for Adimmune Corporation from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -18.85% | -26.51% |
| 2025 | -25.65% | 33.52% |
| 2024 | -19.21% | -52.56% |
| 2023 | -40.49% | -1,024.43% |
| 2022 | 4.38% | -232.73% |
| 2021 | -3.30% | 139.13% |
| 2020 | -1.38% | -94.00% |
| 2019 | -23.00% | -73.92% |
| 2018 | -88.19% | -29.63% |
| 2017 | -125.32% | 28.47% |
| 2016 | -97.55% | -61.54% |
| 2015 | -253.67% | 88.21% |
| 2014 | -134.78% | -13.67% |
| 2013 | -156.12% | -9.31% |
| 2012 | -172.15% | -13.98% |
| 2011 | -200.13% | -856.35% |
| 2010 | 26.46% | -51.05% |
| 2009 | 54.06% | -216.66% |
| 2008 | -46.34% | 215.45% |
| 2007 | -14.69% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -102.05% |
US
|
|
| -149.01% | -92.09% |
US
|
|
| 25.57% | -101.36% |
AU
|
|
| 31.23% | -101.66% |
BE
|
|
| 29.35% | -101.56% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Adimmune Corporation's operating margin
What is Adimmune Corporation's operating margin?
Adimmune Corporation's operating margin is -18.85%, as of Nov 2026.
What was Adimmune Corporation's operating margin in 2025?
In 2025, Adimmune Corporation's operating margin was -25.65%, compared with -19.21% in 2024.
How has Adimmune Corporation's operating margin changed since 2020?
From 2020 to 2025, Adimmune Corporation's operating margin was highest in 2022 (4.38%) and lowest in 2023 (-40.49%).
How does Adimmune Corporation's operating margin compare with similar companies?
Adimmune Corporation's operating margin (-18.85%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.